Jcar-017 Cd19-Specific Chimeric Antigen Receptor
Diffuse Large B-Cell Lymphoma
Explore 253 assets in Diffuse Large B-Cell Lymphoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Lyell Immunopharma, Inc.
Modality
Cell therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07188558CT.gov A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | — | Recruiting | — | — | — |
NCT05633615CT.gov Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05621096CT.gov Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05359211CT.gov NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04855253CT.gov Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | — | Suspended | — | — | — |
NCT03744676CT.gov A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | — | Completed | — | — | — |
NCT03483103CT.gov Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | — | Completed | — | — | — |
NCT03436771CT.gov Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | Terminated | — | — | — |
NCT03310619CT.gov A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT02631044CT.gov Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | — | Completed | — | — | — |
NCT04400591CT.gov Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jcar-017 Cd19-Specific Chimeric Antigen Receptor (this asset) | Lyell Immunopharma, Inc. | P3 | BB · 66 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Jcar-017 Cd19-Specific Chimeric Antigen Receptor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BB · 65 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P2 | BB · 65 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jcar-017 Cd19-Specific Chimeric Antigen Receptor in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jcar-017-cd19-specific-chimeric-antigen-receptor-diffuse-large-b-cell-lymphoma-125954
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →